Online inquiry

IVTScrip™ mRNA-Human ARFGAP3, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK26771MR)

This product GTTS-WK26771MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARFGAP3 protein. This product can be used in Meiotic prophase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001142293.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 26286
UniProt ID Q9NP61
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARFGAP3, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK26771MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WK28058MR IVTScrip™ mRNA-Human ARMC9, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARMC9
GTTS-WK8778MR IVTScrip™ mRNA-Human ABLIM1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABLIM1
GTTS-WK5385MR IVTScrip™ mRNA-Human FSHR, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FSHR
GTTS-WK17319MR IVTScrip™ mRNA-Human ANKRD36, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ANKRD36
GTTS-WK15136MR IVTScrip™ mRNA-Human alpha-Sarcoglycan, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA alpha-Sarcoglycan
GTTS-WK28270MR IVTScrip™ mRNA-Human ARFGAP2, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARFGAP2
GTTS-WK25077MR IVTScrip™ mRNA-Human ARRDC1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARRDC1
GTTS-WK9799MR IVTScrip™ mRNA-Human ADAMTS14, (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADAMTS14
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW